Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Dimethyl Sulfoxide | HCID 679 | — |
| Reactant | Sodium Bicarbonate | HCID 516892 | — |
| Reactant | Artesunate | HCID 6917864 | — |
| Catalyst | Carbon monooxide--dichlororuthenium (3/1) | HCID 10951331 | — |
| Product | Artesunate | HCID 6917864 | — |
| Product | Sodium;4-oxo-4-[[(1R,4S,5R,8S,9R,10R,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoate | HCID 23697153 | — |
Reaction Steps
CORM-2 (Sigma-Aldrich) and Compound 2 were solubilized using 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) in PBS. CORM-3 and Compound 1 were solubilized in PBS (1×). CORM-2 solution (20 mg/kg of body weight) was administered intravenously (i.v.) according to the chosen schedules. Compound 2, CORM-3 and Compound 1 were administered i.v. at equimolar concentrations relative to CORM-2 (36.7 mg/Kg). As vehicle control, we used a solution of 10% DMSO in PBS administered i.v. The concentrations of CORM-2 used in the present study were based on previous reports (see, e.g., Chen et al. Am. J. Pathol. (2009) 175:422-429; Sun et al., World. J. Gastroenterol. (2008) 14:547-553). Artesunate is presented as a powder of artesunic acid. Artesunate (AS) solution was prepared by dissolving 60 mg of anhydrous artesunic acid in 1 ml of sodium bicarbonate (5%) to form sodium artesunate and then diluted in 5 ml of NaCl (0.9%). An AS solution (i.p.) was administered at 40 mg/Kg/day, as described previously (see, e.g., Bienvenu, Acta Trop (2008) 106:104-108). The AS treatment was started when the infected non-treated mice presented the clinical stage 1 for experimental cerebral malaria.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09062089B2 |
|---|
| Source dataset | uspto-grants-2015_06 |
|---|
| ORD ID | ord-40e8dc03b0da4e088a57305f09857ed8 |
|---|
| Source note | uspto-grants-2015_06 |
|---|